Corda Investment Management Lifted Novartis Ag Adr (NVS) Stake; Varian Medical Systems, Inc. (VAR) Had 3 Analysts Last Week

December 1, 2017 - By Marie Mckinney

Corda Investment Management Llc increased Novartis Ag Adr (NVS) stake by 9.09% reported in 2017Q2 SEC filing. Corda Investment Management Llc acquired 11,390 shares as Novartis Ag Adr (NVS)’s stock rose 4.17%. The Corda Investment Management Llc holds 136,742 shares with $11.41 million value, up from 125,352 last quarter. Novartis Ag Adr now has $201.64 billion valuation. The stock increased 0.30% or $0.25 during the last trading session, reaching $86.06. About 1.02 million shares traded. Novartis AG (NYSE:NVS) has risen 7.67% since December 1, 2016 and is uptrending. It has underperformed by 9.03% the S&P500.

Among 11 analysts covering Varian Medical Systems Inc. (NYSE:VAR), 3 have Buy rating, 1 Sell and 7 Hold. Therefore 27% are positive. Varian Medical Systems Inc. had 30 analyst reports since August 27, 2015 according to SRatingsIntel. On Monday, January 23 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The rating was maintained by Jefferies with “Buy” on Friday, July 14. As per Thursday, September 7, the company rating was downgraded by BTIG Research. RBC Capital Markets maintained Varian Medical Systems, Inc. (NYSE:VAR) rating on Wednesday, June 21. RBC Capital Markets has “Hold” rating and $9600 target. Barrington Research maintained the stock with “Outperform” rating in Friday, January 27 report. The firm has “Buy” rating by Citigroup given on Monday, May 8. Brean Capital maintained the stock with “Buy” rating in Thursday, April 28 report. The rating was reinitiated by Barrington Research with “Outperform” on Tuesday, January 12. Robert W. Baird maintained Varian Medical Systems, Inc. (NYSE:VAR) on Thursday, October 26 with “Hold” rating. RBC Capital Markets maintained Varian Medical Systems, Inc. (NYSE:VAR) rating on Thursday, November 30. RBC Capital Markets has “Hold” rating and $105.0 target. See Varian Medical Systems, Inc. (NYSE:VAR) latest ratings:

30/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $105.0 Maintain
30/10/2017 Broker: Citigroup Rating: Neutral Old Target: $119 New Target: $121 Maintain
26/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $99.0 Maintain
25/10/2017 Broker: Jefferies Rating: Buy New Target: $114.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $100.0 Maintain
10/09/2017 Broker: Jefferies Rating: Buy New Target: $115.0 Maintain
07/09/2017 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
01/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $100.0 Maintain
28/08/2017 Broker: Robert W. Baird Rating: Hold New Target: $99.0 Maintain
24/07/2017 Broker: RBC Capital Markets Rating: Hold New Target: $96.0000 Maintain

Among 15 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 3 Sell and 7 Hold. Therefore 33% are positive. Novartis Ag had 33 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was upgraded by Societe Generale on Wednesday, March 8 to “Buy”. Leerink Swann downgraded the stock to “Market Perform” rating in Wednesday, March 23 report. The firm has “Neutral” rating by Credit Suisse given on Wednesday, January 11. The stock of Novartis AG (NYSE:NVS) earned “Neutral” rating by JP Morgan on Tuesday, January 3. On Monday, July 10 the stock rating was maintained by Cowen & Co with “Hold”. The stock of Novartis AG (NYSE:NVS) earned “Underperform” rating by Morgan Stanley on Tuesday, April 12. The rating was maintained by JP Morgan on Wednesday, April 19 with “Neutral”. Credit Suisse downgraded the shares of NVS in report on Wednesday, July 5 to “Underperform” rating. The firm earned “Hold” rating on Friday, October 13 by Cowen & Co. The firm has “Hold” rating by Argus Research given on Tuesday, April 5.

Varian Medical Systems, Inc. designs, makes, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. The company has market cap of $10.32 billion. It operates through two divisions, Oncology Systems and Imaging Components. It has a 37.09 P/E ratio. The Oncology Systems segment provides hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy.

Investors sentiment increased to 0.95 in Q2 2017. Its up 0.04, from 0.91 in 2017Q1. It is positive, as 33 investors sold Varian Medical Systems, Inc. shares while 184 reduced holdings. 74 funds opened positions while 133 raised stakes. 90.12 million shares or 0.48% more from 89.68 million shares in 2017Q1 were reported. Grassi Invest Mgmt owns 16,000 shares for 0.29% of their portfolio. Connecticut-based Sivik Global has invested 0.94% in Varian Medical Systems, Inc. (NYSE:VAR). Fagan Assocs reported 4,000 shares. First Allied Advisory Services Inc invested in 0.01% or 2,190 shares. Millennium Mgmt Ltd Liability Corporation stated it has 0.02% of its portfolio in Varian Medical Systems, Inc. (NYSE:VAR). Chicago Equity owns 0.08% invested in Varian Medical Systems, Inc. (NYSE:VAR) for 29,495 shares. Gradient Investments Limited Liability holds 1 shares. Cohen Klingenstein Limited Com has 0.29% invested in Varian Medical Systems, Inc. (NYSE:VAR). Cetera Advisor Lc stated it has 2,322 shares. Ajo Limited Partnership has invested 0.15% in Varian Medical Systems, Inc. (NYSE:VAR). Great West Life Assurance Can reported 154,488 shares or 0.04% of all its holdings. 55,417 were reported by Jefferies Limited Liability Corp. 4,600 are owned by North Star Asset Mgmt. Gemmer Asset Ltd Com has 0% invested in Varian Medical Systems, Inc. (NYSE:VAR). Oregon Public Employees Retirement Fund has invested 0.06% in Varian Medical Systems, Inc. (NYSE:VAR).

The stock increased 0.83% or $0.93 during the last trading session, reaching $112.68. About 511,894 shares traded. Varian Medical Systems, Inc. (NYSE:VAR) has risen 29.46% since December 1, 2016 and is uptrending. It has outperformed by 12.76% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>